NeoGenomics Announces CEO Departure and Initiates CEO Search
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
NeoGenomics (NEO) Stock Plunges as CEO Abruptly Resigns and Co. Warns for Q1, Prompting Two Street Downgrades
March 29, 2022 9:12 AM EDTNeoGenomics (NASDAQ: NEO) shares have collapsed 29% in pre-open trading Tuesday after announcing that CEO Mark Mallon will be stepping down from the top role and the board. In addition, the company said it now sees first-quarter revenue below the low end of its prior guidance of $118 - $120 million and EBITDA for the quarter below the low end... More
Neogenomics (NEO) PT Lowered to $24 at Cowen
March 29, 2022 7:12 AM EDTCowen analyst Dan Brennan lowered the price target on Neogenomics (NASDAQ: NEO) to $24.00 (from $42.00) while maintaining an Outperform rating after the CEO resigned and Q1 was lowered.
The analyst commented, "Following news of a sudden CEO departure, limited visibility on new... More
Neogenomics (NEO) PT Lowered to $19 at Needham & Company
March 29, 2022 6:34 AM EDTNeedham & Company analyst Mike Matson lowered the price target on Neogenomics (NASDAQ: NEO) to $19.00 (from $29.00) while maintaining a Buy rating.
The analyst commented, "NEO announced the departure of CEO Mark Mallon. We believe that this was not a voluntary decision and may... More
